Zheng Quan Shi Bao·2025-08-10 23:59Core Viewpoint - *ST Sailong, a pharmaceutical company engaged in the full industry chain of drug intermediates, raw materials, formulations, and technical services, faces delisting risk due to negative financial performance in 2024, with a revenue of 264 million yuan and a net profit of -33.14 million yuan [2] Group 1: Financial Performance - In 2024, *ST Sailong achieved an operating income of 264 million yuan and a net profit attributable to shareholders of -33.14 million yuan [2] - The company reported negative values for total profit, net profit, and net profit after deducting non-recurring gains and losses, with operating income below 300 million yuan [2] Group 2: Share Transfer Agreement - On May 18, 2025, the controlling shareholders Cai Nanguai and Tang Lin signed a share transfer agreement with Hainan Yayi, transferring 14.16% of the company's shares, totaling 24.9122 million shares at a price of 8 yuan per share, amounting to 199 million yuan [2] - Following the completion of the share transfer, the controlling shareholder will change from Cai Nanguai and Tang Lin to Hainan Yayi, which currently has no actual controller, resulting in *ST Sailong having no actual controller [2] Group 3: Board Changes - On August 10, 2025, *ST Sailong announced the resignation of several board members, including the chairman and president Cai Nanguai, and the appointment of new non-independent board member candidates [3] - The board approved the appointment of Chen Ke as the new president, who has a background in accounting and investment [4]